VALANX Biotech Shines Again at RESI London Pitch Challenge

From December 4th to 6th, VALANX Biotech participated in the RESI London Pitch Challenge, hosted by Life Science Nation (LSN). This recognized event brought together innovative startups, investors, and licensing partners. “RESI London is your gateway to global early-stage investment in life sciences”, the official LinkedIn page stated.

Building on the success of RESI Boston earlier this year, VALANX was once again recognized as one of the Judges’ Picks, earning top scores for its groundbreaking technology. Competing among 20 startups grouped into 5 sessions, VALANX stood out for its ability to articulate the transformative potential of conjugation site optimization for next-generation antibody-drug conjugates (ADCs).

 

VALANX’s innovative approach to protein conjugation aims to unlock the full potential of ADCs, paving the way for more effective therapeutics. Our participation at RESI London reaffirmed the value of our technology and the strong trajectory of our work.

Michael Lukesch, CEO of VALANX Biotech, reflected on the experience: “I have learned to love pitching. Pitching our technology for the next-generation antibody-drug-conjugates at Life Science Nation’s RESI London was a really good experience. The jury was engaged and asked thoughtful questions conveying deep insights.”

One of the jury members shared their impression, saying: “I really like your vision.”

Recognition at RESI London reaffirms the impact of VALANX’s work and highlights our commitment to advancing protein conjugates to their full potential. With an exciting trajectory ahead, VALANX is poised to continue shaping the future of ADCs and life sciences innovation, while steadily growing its presence in the Life Sciences Ecosystem.